Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella

Federal University of Pará. Institute of Biological Sciences. Human Cytogenetics Laboratory. Belém, PA, Brazil.Federal University of Pará. Institute of Biological Sciences. Human Cytogenetics Laboratory. Belém, PA, Brazil.Federal University of Pará. Institute of Biological Sciences. Human Cytogenetics Laboratory. Belém, PA, Brazil.University of São Paulo. Heart Institute. Medical School Hospital. São Paulo, SP, Brazil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Centro Nacional de Primatas. Ananindeua, PA, Brasil.Federal University of Pará. Institute of Biological Sciences. Human Cytogenetics Laboratory. Belém, PA, Brazil.Federal University of Ceará. Health Sciences Center. Department of Clinical Dentistry. Fortaleza, CE, Brazil.State University of Pará. Post Graduate Program of Amazon Parasitic Biology, Biological and Health Sciences Center. Molecular Biology Laboratory. Belém, PA, Brazil.University of Sao Paulo. Heart Institute. Medical School Hospital . São Paulo, SP, Brazil.Federal University of Pará. Institute of Biological Sciences. Human Cytogenetics Laboratory. Belém, PA, Brazil.Lipid-based nanoparticle systems have been used as vehicles for chemotherapeutic agents in experimental cancer treatments. Those systems have generally been credited with attenuating the severe toxicity of chemotherapeutic agents. This study aimed to investigate the effects of associating paclitaxel (PTX) with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella, documenting the toxicity as measured by serum biochemistry, which is a detailed analysis of blood and tissue. Eighteen C. apella were studied: three animals were treated with cholesterol-rich nanoemulsion (LDE) only, without PTX, administered intravenously every 3 weeks, during six treatment cycles; six animals were treated with PTX associated with LDE at the same administration scheme, three with lower (175 mg/m2 ) and three with higher (250 mg/m2 ) PTX doses; and six animals were treated with commercial PTX, three with the lower and three with the higher doses. In the LDE-PTX group, no clinical toxicity appeared, and the weight–food consumption curve was similar to that of the controls. Two animals treated with commercial PTX presented weight loss, nausea and vomiting, diarrhea, skin flaking, 70% loss of body hair, and decreased physical activity. The use of LDE as a carrier at both lower and higher doses reduced the toxicity of the drug in this species, which is closely related to human subjects. This was observed not only by clinical, biochemical, and hematological profiles but also by the histopathological analysis. The results of this study support the assumption that lipid-based nanoparticle systems used as drug carriers can serve as valuable tools to decrease the toxicity and increase the safety of chemotherapeutic agents